Scancell Holdings Regulatory News (SCLP)

21 October 2020

Scancell Holdings plc

("Scancell" or the "Company")

Notice of Annual General Meeting

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that the Company's Annual General Meeting ("AGM") will take place on Tuesday, 17th November 2020 at 14:00 GMT and the Notice of AGM has been posted to shareholders today. A copy of the Notice has been uploaded to Scancell's website: www.scancell.co.uk/documents-presentations 

The Company continues to monitor the COVID-19 situation closely, including UK Government legislation and guidance, and will continue to do so in the lead up to the AGM. In line with the current UK Government advice, the Board of Directors of the Company (the "Directors" or the "Board") has taken the decision that shareholders, advisers and other guests will not be allowed to attend the AGM in person and anyone seeking to attend the AGM will not be permitted entry.

In light of these measures, the Board strongly encourages shareholders to vote by proxy in accordance with the instructions in the Notice of AGM.

In order to provide shareholders with the opportunity to ask questions at the AGM, the Company will set up the following:

· A recorded presentation by the Company's management team outlining the Company's progress will be uploaded to the Company's website by 16:00 GMT on Monday, 9th November.

· Shareholders will be given the opportunity to email questions to the Board which must be received by 10:00 GMT on Friday, 13th November. The email address for these questions is investor.enquiries@scancell.co.uk. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory announcements.

· Shareholders will be able to dial into the formal AGM on Tuesday, 17th November when the previously submitted questions will be addressed by the Board. The phone number for the dial in will be available on the Company's website on the morning of the AGM.

For further information, please contact:

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its technology platforms, ImmunoBody®, Moditope® and AvidiMabTM, with four products in multiple cancer indications and development of a vaccine for COVID-19.

ImmunoBody® vaccines target dendritic cells and stimulate both CD4 and CD8 T cells with the ability to identify, target and eliminate cancer cells. These cancer vaccines have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. The Directors believe that this platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

· SCIB1, Scancell's lead product, is being developed for the treatment of metastatic melanoma. In a Phase 1/2 clinical trial, survival with SCIB1 treatment appears superior to historical survival rates, with 14 of 16 resected patients receiving 2-4 mg doses of SCIB1 surviving for more than five years (as reported in February 2018).

· SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK (CRUK) for SCIB2.

DNA vaccine against COVID-19: As research data emerges, it is becoming increasingly clear that the induction of potent and activated T cells may play a critical role in the development of long-term immunity and clearance of virus-infected cells. Initial research is underway and Scancell anticipates initiating a Phase 1 clinical trial known as COVIDITY during 2021.

Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). Examples of such modifications are citrullination, an enzyme-based conversion of arginine to citrulline, and homocitrullination (or carbamylation), in which lysine residues are converted to homocitrulline. Expression of peptides containing these modifications have been demonstrated to induce potent CD4 cytotoxic T-cells to eliminate cancer. Previous pre-clinical studies have demonstrated that conjugation of these Moditope® peptides to Amplivant® enhances anti-tumour immune responses 10-100 fold and resulted in highly efficient tumour eradication, including protection against tumour recurrence.

· Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide each conjugated to Amplivant®. Vimentin and enolase peptides are highly expressed in triple negative breast, ovarian, head and neck, and renal cancer, as well as many other cancers. The Company continues to progress the Modi-1 Phase 1/2 clinical trial for regulatory submission to start the planned clinical study in the UK in the first half of 2021.

AvidiMab™ has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody (mAb) including those being developed for autoimmune diseases, as well as cancer. Scancell's development pipeline includes mAbs against specific tumour-associated glycans (TaGs) with superior affinity and selectivity profiles, that have now been further engineered using the Company's AvidiMab™ technology; this confers the Scancell anti-TaG mAbs with the ability to directly kill tumour cells. The Company has entered into three non-exclusive research agreements with leading antibody technology companies to evaluate the Company's anti-TaG mAbs including those enhanced with the AvidiMab™ technology.